Blogs

Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis

By - AMS posted Apr 01, 2020 01:00 PM

  
Volume 32, Issue 7, November 2021, Page 693-700
.
0 comments
0 views

Permalink